Edition:
India

Mersana Therapeutics Says XMT-1522 Development Discontinued Following Strategic Evaluation


Friday, 4 Jan 2019 

Jan 4 (Reuters) - Mersana Therapeutics Inc ::MERSANA THERAPEUTICS ANNOUNCES STRATEGIC PRIORITIES AND GOALS FOR 2019 AND BEYOND.MERSANA THERAPEUTICS INC - XMT-1522 DEVELOPMENT DISCONTINUED FOLLOWING STRATEGIC EVALUATION.MERSANA THERAPEUTICS INC - DOSE SELECTION AND INITIATION OF XMT-1536 EXPANSION COHORTS ON TRACK FOR FIRST HALF 2019.MERSANA THERAPEUTICS - TO FOCUS RESOURCES ON ADVANCING XMT-1536, ITS FIRST-IN-CLASS ADC CANDIDATE TARGETING NAPI2B, SHOWING ENCOURAGING EARLY SIGNS OF EFFICACY.MERSANA THERAPEUTICS - FOR XMT-1536, EXPECTS TO SELECT DOSE FOR USE IN PHASE 1 EXPANSION STUDIES, INITIATE ENROLLMENT OF PATIENTS IN EXPANSION COHORTS IN H1 2019.MERSANA THERAPEUTICS INC - EXPECTS TO DISCLOSE ITS NEXT CLINICAL CANDIDATE IN SECOND HALF OF 2019.MERSANA THERAPEUTICS INC - MERSANA AND ITS PARTNER, TAKEDA, PLAN TO TERMINATE CO-DEVELOPMENT COLLABORATION FOR XMT-1522.MERSANA THERAPEUTICS INC - TARGETING FILING OF IND APPLICATION WITH FDA IN FIRST HALF OF 2020.MERSANA THERAPEUTICS INC - PROACTIVELY EVALUATING POTENTIAL FOR STRATEGIC COLLABORATIONS.